Vaxine intellectual property

Advax(TM) is the trademark for a family of polysaccharide-based vaccine adjuvants developed by Vaxine. To protect the Advax family of delta inulin adjuvants, Vaxine has been granted multiple international patents. In addition to its adjuvant patent portfolio, Vaxine also holds international patents over a vaccine technology to prevent type 1 (autoimmune) diabetes.  Vaxine is currently actively seeking additional licensing and/or development partners with respect to its vaccine technologies.